Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01380535 · ClinicalTrials.gov registry record · Early Phase 1
Extracorporeal Photopheresis (ECP) With Methoxsalen for Chronic Graft Versus Host Disease (cGVHD)
A Early Phase 1 study, sponsored by Mallinckrodt.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 60
- Enrollment target
NCT01380535 is a Early Phase 1 study that has completed, run by Mallinckrodt. The registered enrollment target is 60 participants.
The verdict
NCT01380535, a Early Phase 1 study, has completed, sponsored by Mallinckrodt.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
Chronic graft-versus-host disease (cGVHD) is a long-lasting complication that can occur after transplants. The transplanted cells seem to fight with the patient's own cells. Extracorporeal photopheresis (ECP) is a fairly new procedure for cGVHD. The participant gets a port to hook up to a machine. The machine removes the white blood cells, mixes them with a light-sensitive drug, shines light on it, and puts all the blood back in. This study will find out if patients respond better if they get ECP with methoxsalen, in addition to the pills normally used to treat cGVHD.
Interventions
- DRUG Standard of Care
- DRUG ECP Methoxsalen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2011-11 |
| Est. Completion | 2015-03 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01380535
The ClinicalTrials.gov registry entry for NCT01380535 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mallinckrodt, which has 69 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Standard of Care is the first listed.
NCT01380535 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01380535 about?
NCT01380535 is a clinical study titled "Extracorporeal Photopheresis (ECP) With Methoxsalen for Chronic Graft Versus Host Disease (cGVHD)". Chronic graft-versus-host disease (cGVHD) is a long-lasting complication that can occur after transplants. The transplanted cells seem to fight with the patient's own cells. Extracorporeal photopheresis (ECP) is a fairly new procedure for cGVHD. The participant gets a port to hook up to a machine. ...
What is the current status of trial NCT01380535?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 60 participants. The study started on 2011-11. Estimated completion is 2015-03.
What interventions are being tested in trial NCT01380535?
The interventions under investigation include: Standard of Care (DRUG), ECP Methoxsalen (DRUG).
Who is sponsoring clinical trial NCT01380535?
This trial is sponsored by Mallinckrodt, which has 69 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.